Open

Topical for Hidradenitis Suppurativa

The purpose of the study is to learn about the safety and effects of the study medicine (called Ruxolitinib Cream) for the treatment of Hidradenitis Suppurativa in participants at least 12 years of age with mild to moderate HS.

Age & Gender

12 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

At each visit, you will meet with a member of the study team and fill out questionnaires. The study also involves vital signs, blood draws, urine testing, physical exams, willingness to provide medical history and use of medications, use of birth control method if applicable, and willingness to take the study medication as directed.

Incentives

Information provided upon request

In-person visits:
17

Total length of participation:
60 weeks

Looking for Specific Volunteers

Able to participate:

you are 12 years or older
Diagnosis of HS for at least 6 months before the 1st visit
agree to not use topical or systemic antibiotics for treatment of HS
Willingness to avoid pregnancy or fathering children

Not eligible if:

history of malignancies within 5 years
Unstable asthma or COPD requiring systemic treatment
Severe anemia, severe thrombocytopenia, or severe neutropenia.
Clinically uncontrolled cardiovascular disease
Pregnant or lactating.

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Primary Visit Location

Dermatology Clinical Trials Unit (DCTU)
UNC Dermatology and Skin Cancer Center at Southern Village
410 Market St Ste 362, Chapel Hill, NC 27516, USA

Additional Study Information

Principal Investigator

Chris Sayed
Dermatology - Adult

Study Type

Clinical or Medical
Interventional

Study Topics

Skin, Hair, and Nails

IRB Number

25-1263

ClinicalTrials.gov

NCT06959225

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.